Clinical Trials on Giant Cell Tumors in New Zealand

Total 7644 results

GlaxoSmithKline

Completed

Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects

Leukaemia, Lymphocytic, Chronic

Australia, United States, New Zealand
Zealand University Hospital

Completed

Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer

Metastatic Nonsmall Cell Lung Cancer

Denmark
Philip Friedlander
Genentech, Inc.

Terminated

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Novartis; National Comprehensive Cancer Network

Completed

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

Melanoma

United States
NYU Langone Health

Terminated

A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb

Completed

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

Melanoma

United States
Genta Incorporated

Unknown

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Melanoma

United States
Prof. Dr. med. Dirk Schadendorf
Bristol-Myers Squibb

Active, not recruiting

Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation (ADMEC-O)

Merkel Cell Carcinoma

Germany, Netherlands
Viralytics

Completed

Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) (CAPRA)

Melanoma

United States
National Cancer Institute (NCI)
Children's Cancer Group

Completed

Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

Sarcoma | Neutropenia

United States, Puerto Rico, Canada, Switzerland, Australia
Antonio Fojo
Ipsen

Recruiting

LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) (LAMPARA)

Pheochromocytoma | Paraganglioma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Metastatic Merkel Cell Carcinoma | Refractory Merkel Cell Carcinoma | Locally Advanced Merkel Cell Carcinoma | Unresectable Merkel Cell Carcinoma | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Melanoma (Skin)

United States
GE Healthcare

Approved for marketing

Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma

Neuroblastoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumor | Metastatic Malignant Neoplasm in the Liver | Stage I Pancreatic Neuroendocrine Tumor AJCC v8 | Stage II Pancreatic Neuroendocrine Tumor AJCC v8 | Stage III Pancreatic Neuroendocrine Tumor AJCC v8

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation

Neuroblastoma

United States
Xencor, Inc.

Recruiting

Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors

Testicular Germ Cell Tumor | Ovarian Cancer | Endometrial Cancer | Ovarian Germ Cell Tumor | Germ Cell Tumor

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Neuroblastoma | High-Risk

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

Neuroblastoma (NB)

United States
National Cancer Institute (NCI)

Completed

Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

Childhood Chronic Myelogenous Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Childhood Rhabdomyosarcoma | Metastatic Osteosarcoma | Disseminated Neuroblastoma | Previously Treated... and other conditions

United States
Amgen

Completed

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Sarcoma | Lymphoma | Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumors | Metastatic Cancer | Solid Tumors | Carcinoid | Locally Advanced

United States, Spain, Poland
BeiGene

Completed

Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

Solid Tumors

Australia, New Zealand
NeoImmuneTech
Immune Oncology Network

Terminated

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Melanoma | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
New Mexico Cancer Care Alliance

Completed

The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure

Melanoma

United States
MELA Sciences, Inc.

Completed

Does the Aid of MelaFind Affect Clinical Management Decisions

Melanoma

United States
AbbVie

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)

Giant Cell Arteritis (GCA)

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Romania, Russian Federation, Spain, Sweden, Switzerland, United...
Memorial Sloan Kettering Cancer Center
University of British Columbia; San Diego State University; Stony Brook University

Active, not recruiting

Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Schering-Plough

Completed

Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Rockefeller University

Completed

Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Pfizer

Completed

Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma

Melanoma

United States
Dr. Nina Bhardwaj
Cancer Research Institute, New York City

Completed

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Melanoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors

Sarcoma | Unspecified Childhood Solid Tumor, Protocol Specific | Neuroblastoma | Melanoma (Skin)

United States, Canada, Australia
Memorial Sloan Kettering Cancer Center
Array BioPharma

Completed

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine; Weill Medical College of Cornell... and other collaborators

Recruiting

Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics; Band of Parents

Completed

Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Terminated

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow

Neuroblastoma

United States
Columbia University

Terminated

Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

No longer available

Naxitamab and GM-CSF in People With Neuroblastoma

High-Risk Neuroblastoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Refractory Melanoma | HLA-A2 Positive Cells Present

United States
Novartis Pharmaceuticals

Completed

A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Recurrent or Refractory Medulloblastoma | Locally Advanced or Metastatic Basal Cell Carcinoma

United States, United Kingdom, Switzerland, Netherlands
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Melanoma | Solid Tumor | Metastatic Cancer | Advanced Cancer | Head and Neck Squamous Cell Carcinoma | Kaposi Sarcoma | Merkel Cell Carcinoma | Angiosarcoma | Basal Cell Carcinoma | Extramammary Paget Disease | HNSCC | Refractory Cancer | Cutaneous Squamous Cell Carcinoma | BCC | Adnexal Carcinoma | BCC - Basal Cell Carcinoma and other conditions

United States
Xencor, Inc.
ICON plc

Completed

A Study of XmAb®18087 in Subjects With NET and GIST

Neuroendocrine Tumor | Gastrointestinal Neoplasm

United States
NYU Langone Health

Terminated

Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma

Metastatic Melanoma

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma

Melanoma (Skin)

United States
Hoffmann-La Roche

Recruiting

A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma

Melanoma

Brazil, Czechia, Spain, Turkey, New Zealand, Canada, Australia, Poland, Slovakia, Greece

Clinical Trials on Giant Cell Tumors in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations